Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

AI TECHNOLOGY GROUP INC

AIPGOTCEQUITYCurrent

Other Events

Item 8.01 Other Events January 12, 2026, the Registrant and AVM Biotechnology, Inc. (“AVM”) issued a joint press release regarding the Registrant’s funding efforts and certain information regarding AVM. Section 9 - Financial Statements and Exhibits

Filed Jan 14, 2026Accepted Jan 14, 2026, 4:08 PM ESTCIK 1289047Accession 0001477932-26-000202
Share

Company context

Current securities

Recent company filings

  1. Changes in Registrant's Certifying AccountantOct 2, 2026
  2. Entry into a Material Definitive AgreementJun 12, 2026
  3. NT 10-Q filingMay 18, 2026
  4. D filingApr 24, 2026
  5. NT 10-K filingMar 30, 2026

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events January 12, 2026, the Registrant and AVM Biotechnology, Inc. (“AVM”) issued a joint press release regarding the Registrant’s funding efforts and certain information regarding AVM. Section 9 - Financial Statements and Exhibits
Filed exhibits (1)
EX-99.1 (by filename) aipg_ex991.htm

EXHIBIT 99.1 AI Technology Group Inc. PRESS RELEASE January 12, 2026 Ai Technology Group Inc. (the “Company”) and AVM Biotechnology Inc. (“AVM”, the Washington State company that is the subject of the proposed merger) provide this joint press release. The Company continues with the funding of their proposed merger with AVM on an exclusive basis and announces we are in the process of extending funding dates to accommodate extended merger and financial audit timelines. The Company and AVM look forward to the planned merger during 2026 to continue and facilitate corporate growth of the combined entities. In addition, AVM has re-commenced its FDA Phase 2 Clinical Trial on relapsed and refractory Non- Hodgkins Lymphoma (“OPAL Trial”) for their small molecule immunomodulatory drug, AVM0703, working with Insight 68 an innovative Ai-driven platform company that drives digital transformation and scales to meet all corporate needs in clinical trials, scheduling, planning, manufacturing, and logistics. AVM expects to enroll an additional 7-10 more patients followed by submission to the FDA for review. AVM0703 has been administered in 3-4 week cycles for up to 9 repeat infusions withou…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.